Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Step by step instructions to Protect Your Retirement with Senior Protection.- The Tradition of Stone: A Gander at Notable Structures Through the Ages
- Step by step instructions to Show Children the Significance of Appropriate Handshaking
- The most effective method to Decide the Best Auto Crash Attorney for Your Lawful Necessities
- Vietnam rethinks its flood strategy as climate change drives storms and devastation
- South Carolina measles outbreak grows by nearly 100, spreads to North Carolina and Ohio
- Inconceivable Spots To Stargaze All over The Planet
- Step by step instructions to Involve Compact disc Rates for Magnanimous Giving
- The most effective method to Safeguard Your Teeth from Acidic Food varieties and Beverages
